Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma

Authors

  • Jun Yong Park MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Sang Hoon Ahn MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Young Joon Yoon MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Ja Kyung Kim MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Hyun Woong Lee MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Do Yun Lee MD,

    1. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    2. Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for more papers by this author
  • Chae Yoon Chon MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Young Myoung Moon MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    Search for more papers by this author
  • Kwang-Hyub Han MD

    Corresponding author
    1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
    2. Yonsei Liver Cancer Special Clinic, Seoul, Republic of Korea
    3. Brain Korea 21 Project for Medical Science, Seoul, Republic of Korea
    • Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul, Republic of Korea
    Search for more papers by this author
    • Fax: (011) 82-2-393-6884


Abstract

BACKGROUND.

Hepatic arterial infusion chemotherapy (HAIC) has often been selected as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). The objective of the current study was to evaluate the efficacy and safety of repetitive HAIC with high-dose 5-fluorouracil (5-FU) and cisplatin given for 3 days in patients with advanced HCC.

METHODS.

Between January 2001 and December 2004, a total of 41 patients with unresectable advanced HCC were enrolled. The patients underwent HAIC via the implantable port system with 5-FU (at a dose of 500 mg/m2 on Days 1–3) and cisplatin (at a dose of 60 mg/m2 on Day 2) every 4 weeks. Tumor response was assessed at the end of every 3 cycles.

RESULTS.

The median age of the patients was 53 years and 34 patients (82.9%) had evidence of portal vein thrombosis. In total, 230 cycles of HAIC were administered to the 41 patients, with a median of 6 cycles given (range, 1–14 cycles). Nine patients (22.0%) achieved a partial response and 14 patients (34.1%) had stable disease. The median time to disease progression and overall survival were 7.0 months and 12.0 months, respectively. The overall survival was found to be significantly longer in the successful disease control group (patients with a complete response, partial response, and stable disease) than in the disease progression group (median of 14.0 months vs 6.0 months; P < .001). Adverse reactions were tolerable and successfully managed with conservative treatment.

CONCLUSIONS.

HAIC with high-dose 5-FU and cisplatin given for 3 days achieved effective and safe results in patients with advanced HCC. Therefore, repetitive short-course HAIC with high-dose 5-FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC. Cancer 2007. © 2007 American Cancer Society.

Ancillary